Volume 78, Issue 11, Pages (December 2010)

Slides:



Advertisements
Similar presentations
Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T- Cell Depletion in a Murine Mesothelioma Model  Licun Wu, MD, Zhihong.
Advertisements

Inflammatory cytokines in acute renal failure
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells  B. Zhang, G. Ramesh, C.C. Norbury, W.B. Reeves 
Volume 72, Issue 3, Pages (August 2007)
Volume 80, Issue 2, Pages (July 2011)
Volume 65, Issue 4, Pages (April 2004)
Volume 79, Issue 9, Pages (May 2011)
Loss of Extracellular Superoxide Dismutase Induces Severe IL-23-Mediated Skin Inflammation in Mice  Yun Sang Lee, In-Su Cheon, Byung-Hak Kim, Myung-Ja.
Volume 85, Issue 3, Pages (March 2014)
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Volume 81, Issue 2, Pages (January 2012)
Volume 81, Issue 9, Pages (May 2012)
Progranulin protects against renal ischemia/reperfusion injury in mice
Volume 78, Issue 4, Pages (August 2010)
Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus- Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration.
Volume 76, Issue 7, Pages (October 2009)
Li-Wen Lai, Kim-Chong Yong, Yeong-Hau H. Lien  Kidney International 
Volume 84, Issue 3, Pages (September 2013)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Jinu Kim, Kelly E. Long, Kang Tang, Babu J. Padanilam 
Volume 85, Issue 1, Pages (January 2014)
Volume 79, Issue 4, Pages (February 2011)
Volume 82, Issue 8, Pages (October 2012)
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Volume 82, Issue 1, Pages (July 2012)
IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft- Versus-Host Disease  Doanh Le Huu, Takashi Matsushita, Guihua Jin, Yasuhito.
Volume 18, Issue 5, Pages (May 2010)
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Tumor Necrosis Factor-α-Activated Human Adipose Tissue–Derived Mesenchymal Stem Cells Accelerate Cutaneous Wound Healing through Paracrine Mechanisms 
Volume 82, Issue 1, Pages (July 2012)
Volume 63, Issue 1, Pages (January 2003)
Genistein protects the kidney from cisplatin-induced injury
Volume 87, Issue 2, Pages (February 2015)
Volume 140, Issue 7, Pages (June 2011)
Volume 73, Issue 4, Pages (February 2008)
Volume 82, Issue 9, Pages (November 2012)
Volume 143, Issue 1, Pages (July 2012)
Volume 77, Issue 5, Pages (March 2010)
Autophagy in proximal tubules protects against acute kidney injury
Volume 81, Issue 9, Pages (May 2012)
Decreased renal ischemia–reperfusion injury by IL-16 inactivation
Volume 79, Issue 1, Pages (January 2011)
Role of meprin A in renal tubular epithelial cell injury
Gilbert R. Kinsey, Liping Huang, Amy L. Vergis, Li Li, Mark D. Okusa 
Volume 72, Issue 8, Pages (October 2007)
Volume 66, Issue 6, Pages (December 2004)
Volume 72, Issue 3, Pages (August 2007)
Volume 83, Issue 3, Pages (March 2013)
Volume 86, Issue 4, Pages (October 2014)
Volume 66, Issue 3, Pages (September 2004)
Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury  Jianchun Chen, Jian-Kang.
Volume 70, Issue 2, Pages (July 2006)
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Volume 56, Issue 3, Pages (September 1999)
Volume 73, Issue 11, Pages (June 2008)
Genetic deficiency of adiponectin protects against acute kidney injury
Volume 84, Issue 4, Pages (October 2013)
Volume 85, Issue 4, Pages (April 2014)
The pathological role of Bax in cisplatin nephrotoxicity
Volume 81, Issue 2, Pages (January 2012)
Volume 75, Issue 5, Pages (March 2009)
Volume 79, Issue 2, Pages (January 2011)
Volume 88, Issue 6, Pages (December 2015)
Volume 74, Issue 1, Pages (July 2008)
Volume 75, Issue 5, Pages (March 2009)
MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis  Sang-Kyung Jo, Won Yong Cho, Su Ah Sung, Hyoung.
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Volume 20, Issue 6, Pages (June 2012)
Volume 75, Issue 5, Pages (March 2009)
Volume 78, Issue 3, Pages (August 2010)
Presentation transcript:

Volume 78, Issue 11, Pages 1100-1109 (December 2010) CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice  Hyojung Lee, Dukhee Nho, Hwan-Suck Chung, Heekyung Lee, Min-Kyu Shin, Sung-Hoon Kim, Hyunsu Bae  Kidney International  Volume 78, Issue 11, Pages 1100-1109 (December 2010) DOI: 10.1038/ki.2010.139 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Survival in cisplatin-treated mice. All mice received a single dose of cisplatin intraperitoneally (40 mg/kg body weight) and were followed up for up to 96 h. (a) nu/nu Mice had a 69% survival rate, whereas all Balb/c mice expired (***P<0.001 vs Balb/c; n=16 to 21). (b) nu/nu Mice were reconstituted by tail intravenous injection with 1 × 106 CD4+CD25- T cells or CD4+CD25+ Treg cells 10 days before cisplatin administration. CD4+CD25+ Treg cell-reconstituted mice had a longer survival time than did the other mice (***P<0.001 vs cisplatin; n=16). Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 Effect of CD4+CD25+ Treg cells on renal dysfunction in mice.nu/nu Mice were reconstituted by tail intravenous injection with 1 × 106 CD4+CD25- or CD4+CD25+ T cells 10 days before cisplatin administration. Balb/c mice: saline treatment alone (saline (Balb/c)); cisplatin treatment alone (cisplatin (Balb/c)). nu/nu Mice: saline treatment alone (saline); cisplatin treatment alone (cisplatin); transferred CD4+CD25- T-cell and cisplatin treatment (CD4+CD25-); transferred CD4+CD25+ Treg cell and cisplatin treatment (CD4+CD25+). Creatinine and BUN levels were measured at 24 and 48 h, respectively, after saline or cisplatin injection. Changes in creatinine (creatinine 48 h: saline 0.30±0.04 mg/dl; cisplatin 1.2±0.13 mg/dl; CD4+CD25+ 0.79±0.09 mg/dl) and BUN (BUN 48 h: saline 23±2.4 mg/dl; cisplatin 140±15 mg/dl; CD4+CD25+ 80±9.4 mg/dl) levels were measured (*P<0.05, **P<0.01, ***P<0.001, #P<0.001 vs cisplatin, two-tailed paired t-test; n=6 to 7). BUN, blood urea nitrogen; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Effect of CD4+CD25+ Treg cells on renal histology in mice. Sections of kidney were stained with H&E 48 h after cisplatin injection. (a) Saline treatment alone (saline); cisplatin treatment alone (cisplatin); transferred CD4+CD25- T-cell and cisplatin treatment (CD4+CD25-); transferred CD4+CD25+ Treg cell and cisplatin treatment (CD4+CD25+). (b) Tubular injury was scored using the semi-quantitative evaluation method. The CD4+CD25+ Treg cell-injected mice had significantly less tubular injury than did CD4+CD25- T cell-injected mice and cisplatin-treated control mice (**P<0.01, ***P<0.001 vs cisplatin, #P<0.001 vs CD4+CD25+, two-tailed paired t-test; n=4). H&E, hematoxylin and eosin; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 Effect of CD4+CD25+ Treg cells on macrophage infiltration in the kidneys of mice. (a) Accumulation of macrophages in the kidneys was detected by immunostaining of F4/80-positive cells at 48 h after cisplatin administration. Saline treatment alone (saline); cisplatin treatment alone (cisplatin); transferred CD4+CD25- T-cell and cisplatin treatment (CD4+CD25-); transferred CD4+CD25+ Treg cell and cisplatin treatment (CD4+CD25+). (b) The numbers of F4/80-positive cells in each section were counted in 10 fields per slide at an original magnification of × 400. Macrophage infiltration was significantly reduced in CD4+CD25+ Treg cell-reconstituted mice compared with CD4+CD25- T cell-injected mice and cisplatin-treated control mice (**P<0.01, ***P<0.001 vs cisplatin, #P<0.001 vs CD4+CD25+, two-tailed paired t-test; n=4). Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 5 Proinflammatory cytokines in the kidney. Proinflammatory cytokines in the kidney were measured by ELISA at 48 h after cisplatin injection. When compared with cisplatin-treated control mice, the elevation of TNF-α (a; saline 2200±180; cisplatin 4100±290; CD4+CD25- 4531±526.5; CD4+CD25+ 3181±85.20) and IL-1β (b; saline 1200±160; cisplatin 4000±360; CD4+CD25- 3668±515.5; CD4+CD25+ 1969±63.82) was significantly lower in CD4+CD25+ Treg cell-reconstituted mice. (**P<0.01, ***P<0.001 vs cisplatin, #P<0.001 vs CD4+CD25+, two-tailed paired t-test; n=4). ELISA, enzyme-linked immunosorbent assay; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 6 Effect of infused CD4+CD25+ Treg cells on cisplatin nephrotoxicity in Balb/c mice. Balb/c mice were reconstituted by intravenous injection with 3 × 106 CD4+CD25+ T cells 10 days before cisplatin administration. All mice received a single dose of cisplatin or saline intraperitoneally (25 mg/kg body weight). (a) Survival rate and (b) BUN and serum creatinine (b) were measured 24 h after cisplatin administration. (*P<0.05 vs cisplatin; n=5). BUN, blood urea nitrogen; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 7 Effect of CD4+CD25+ Treg cells depletion on cisplatin nephrotoxicity in Balb/c mice. Saline treatment alone (saline); cisplatin treatment alone (cisplatin); anti-CD25 antibody and cisplatin treatment (anti-CD25). (a) Balb/c mice received daily injections of 0.25 mg of anti-CD25 antibody for 3 days before cisplatin administration. The efficacy of CD4+CD25+ Treg cells depletion was confirmed by flow cytometry analysis using PE-anti-mouse CD25 and FITC-anti-mouse CD4 (***P<0.001 vs control, n=4). (b) Creatinine and BUN levels were measured at 24, 48, and 72 h after saline or cisplatin injection. Changes in creatinine and BUN levels were measured (*P<0.05, **P<0.01 vs cisplatin, n=6). (c) Sections of kidney were stained with H&E 72 h after cisplatin injection. Tubular injury was scored using the semi-quantitative evaluation method (*P<0.05 vs cisplatin, n=6). (d) Survival data between CD4+CD25+ Treg cells depletion mice and wild-type Balb/c mice (n=11). BUN, blood urea nitrogen; FITC, fluorescein isothiocyanate; H&E, hematoxylin and eosin; PE, phycoerythrin; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 7 Effect of CD4+CD25+ Treg cells depletion on cisplatin nephrotoxicity in Balb/c mice. Saline treatment alone (saline); cisplatin treatment alone (cisplatin); anti-CD25 antibody and cisplatin treatment (anti-CD25). (a) Balb/c mice received daily injections of 0.25 mg of anti-CD25 antibody for 3 days before cisplatin administration. The efficacy of CD4+CD25+ Treg cells depletion was confirmed by flow cytometry analysis using PE-anti-mouse CD25 and FITC-anti-mouse CD4 (***P<0.001 vs control, n=4). (b) Creatinine and BUN levels were measured at 24, 48, and 72 h after saline or cisplatin injection. Changes in creatinine and BUN levels were measured (*P<0.05, **P<0.01 vs cisplatin, n=6). (c) Sections of kidney were stained with H&E 72 h after cisplatin injection. Tubular injury was scored using the semi-quantitative evaluation method (*P<0.05 vs cisplatin, n=6). (d) Survival data between CD4+CD25+ Treg cells depletion mice and wild-type Balb/c mice (n=11). BUN, blood urea nitrogen; FITC, fluorescein isothiocyanate; H&E, hematoxylin and eosin; PE, phycoerythrin; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 8 Assessment of Foxp3EGFP cell migration into the kidney. (a) 1 × 106 CD4+CD25+Treg cells from Foxp3EGFP Balb/c mice were transferred to one group of nu/nu mice 10 days before cisplatin administration. Splenocytes were isolated from each mouse upon killing and then analyzed by FACS. Foxp3EGFP Balb/c mice had 4.4±0.06% CD4+Foxp3EGFP-positive cells; meanwhile, nu/nu mice had 0.01% CD4+Foxp3EGFP-positive cells in their spleen. At 10 days after an adoptive transfer of Foxp3EGFP Balb/c CD4+CD25+ Treg cells, the average population of CD4+Foxp3EGFP-positive cells was reconstituted up to ***1.8±0.06% (***P<0.001 vs nu/nu). (b) Foxp3-positive cells in nu/nu mice kidneys were detected using a Zeiss LSM5 confocal microscope. The numbers of Foxp3-positive cells in each section were counted in 10 fields per slide (original magnification, × 200, ***P<0.001 vs 0 h, n=3). FACS, fluorescence-activated cell sorting; Treg, T regulatory cell. Kidney International 2010 78, 1100-1109DOI: (10.1038/ki.2010.139) Copyright © 2010 International Society of Nephrology Terms and Conditions